155 related articles for article (PubMed ID: 8235705)
1. Adoptive immunotherapy in human and canine chimeras--the role of interferon alfa. EBMT Chronic Leukemia Working Party.
Kolb HJ; Mittermüller J; Hertenstein H; Schumm M; Holler E; de Witte T; Günther W; Ljungman P; Goldman JM
Semin Hematol; 1993 Jul; 30(3 Suppl 3):37-9. PubMed ID: 8235705
[No Abstract] [Full Text] [Related]
2. Adoptive immunotherapy in human and canine chimeras.
Kolb HJ; Mittermüller J; Günther W; Bartram C; Thalmaier K; Schumm M; Holler E; Lederose G
Bone Marrow Transplant; 1993; 12 Suppl 3():S61-4. PubMed ID: 7510199
[No Abstract] [Full Text] [Related]
3. Prophylactic use of interferon alfa after bone marrow transplantation for patients with chronic myelogenous leukemia at high risk of relapse: a pilot study. The Chronic Leukemia Working Party of the EBMT.
Niederwieser D; Arcese W; Bandini G; Schwaighofer H; Thaler J; Bosi A; Di Bartolomeo P; Alessandrino EP; Urban C; Gratwohl A
Semin Hematol; 1993 Jul; 30(3 Suppl 3):40-3. PubMed ID: 8235706
[No Abstract] [Full Text] [Related]
4. [Cellular immunotherapy in chronic myeloid leukemia].
Fernández MN
Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
[No Abstract] [Full Text] [Related]
5. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1992; 13():327-48. PubMed ID: 1389914
[No Abstract] [Full Text] [Related]
6. Leukemias and myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1990; 11():321-42. PubMed ID: 2223398
[No Abstract] [Full Text] [Related]
7. Leukemias and myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1991; 12():327-46. PubMed ID: 1931449
[No Abstract] [Full Text] [Related]
8. Adoptive immunotherapy with donor lymphocyte transfusions.
Kolb HJ; Holler E
Curr Opin Oncol; 1997 Mar; 9(2):139-45. PubMed ID: 9161791
[TBL] [Abstract][Full Text] [Related]
9. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
10. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy for recurrent CML after BMT.
Helg C; Roux E; Beris P; Cabrol C; Wacker P; Darbellay R; Wyss M; Jeannet M; Chapuis B; Roosnek E
Bone Marrow Transplant; 1993 Aug; 12(2):125-9. PubMed ID: 8401357
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host reactions: anti-leukemia effects of donor T cells.
Flowers ME; Sullivan KM; Deeg HJ
Transplant Proc; 1996 Jun; 28(3):1184-5. PubMed ID: 8658620
[No Abstract] [Full Text] [Related]
13. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
14. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties.
Kolb HJ
Vox Sang; 1998; 74 Suppl 2():321-9. PubMed ID: 9704463
[TBL] [Abstract][Full Text] [Related]
15. DLI or second transplant.
Greinix HT
Ann Hematol; 2002; 81 Suppl 2():S34-5. PubMed ID: 12611068
[TBL] [Abstract][Full Text] [Related]
16. [Donor lymphocyte infusions as adoptive immunotherapy in patients with relapsed hematologic neoplasms post-allogenic transplant of hematopoietic progenitor cells].
Riera L; Koziner B
Medicina (B Aires); 2000; 60(2):259-69. PubMed ID: 10962823
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
18. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
Amrolia PJ; Rao K; Slater O; Ramsay A; Veys PA; Webb DK
Bone Marrow Transplant; 2001 Sep; 28(6):623-5. PubMed ID: 11607779
[TBL] [Abstract][Full Text] [Related]
19. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
20. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
